Abstract
Emerging evidence suggests a class of non-coding RNAs termed microRNAs (miRNAs) play a key role in cancer. Since their original discovery in C. elegans in 1993 it has become evident that miRNAs are responsible for an entirely new mechanism of posttranscriptional gene regulation. miRNA expression is widespread in mammalian cells and notably altered in several cancer types. miRNA expression patterns correlate with several aspects of tumorigenesis and miRNA loci have been mapped to frequently altered cancerassociated genomic regions. Inhibition or augmentation of miRNA expression in cancer cells impacts gene expression and affects cell proliferation and survival. Hence, cancer-associated miRNAs may be regarded as a new class of non-coding tumour suppressors and oncogenes capable of regulating several key signalling pathways.
Current Pharmaceutical Biotechnology
Title: MicroRNAs in Tumorigenesis
Volume: 8 Issue: 6
Author(s): Kai Ove Skaftnesmo, Lars Prestegarden, David R. Micklem and James B. Lorens
Affiliation:
Keywords: RNA, microRNA, cancer
Abstract: Emerging evidence suggests a class of non-coding RNAs termed microRNAs (miRNAs) play a key role in cancer. Since their original discovery in C. elegans in 1993 it has become evident that miRNAs are responsible for an entirely new mechanism of posttranscriptional gene regulation. miRNA expression is widespread in mammalian cells and notably altered in several cancer types. miRNA expression patterns correlate with several aspects of tumorigenesis and miRNA loci have been mapped to frequently altered cancerassociated genomic regions. Inhibition or augmentation of miRNA expression in cancer cells impacts gene expression and affects cell proliferation and survival. Hence, cancer-associated miRNAs may be regarded as a new class of non-coding tumour suppressors and oncogenes capable of regulating several key signalling pathways.
Export Options
About this article
Cite this article as:
Skaftnesmo Ove Kai, Prestegarden Lars, Micklem R. David and Lorens B. James, MicroRNAs in Tumorigenesis, Current Pharmaceutical Biotechnology 2007; 8 (6) . https://dx.doi.org/10.2174/138920107783018390
DOI https://dx.doi.org/10.2174/138920107783018390 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Surface Binding of Toxins and Heavy Metals by Probiotics
Mini-Reviews in Medicinal Chemistry Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs
Current Pharmaceutical Design Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Targeting Apoptosis to Treat Multiple Sclerosis
Current Drug Discovery Technologies T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued) Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology OIP5-AS1: A Fascinating Long Noncoding RNA in Carcinoma
Current Pharmaceutical Design Drug Metabolism and Pharmacokinetics in Support of Drug Design
Current Pharmaceutical Design Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets Chemokines as Pharmacological Targets
Mini-Reviews in Medicinal Chemistry An Update of Radiolabeled Bombesin Analogs for Gastrin-Releasing Peptide Receptor Targeting
Current Pharmaceutical Design Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology Efficient Growth Inhibition of Human Osteosarcoma Cells Using a Peptide Derived from the MDM-2-Binding Site of p53
Protein & Peptide Letters Engineered Nanoparticles in Cancer Therapy
Recent Patents on Drug Delivery & Formulation Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development
Current Pharmaceutical Design